By now, we all might have heard about the new characters in Genshin Impact version 4.7. They have been teased and drip-marketed, which has definitely generated a lot of hype in the community. Players are going crazy over Clorinde and Sigewinne. However, what about the rerun characters?
Worry not, fellow travelers, leaks have been revealed by some trusted sources, suggesting the return of two old fav-favorite characters.
According to the leaks, Alhaitham and Furina will be featured in version 4.7 alongside Clorinde and Sigewinne.
The leaks were revealed by Genshin Impact leaker FullStopChan and conveyed by HxG, one of the oldest and reliable leak sources in the community. Clorinde and Alhaitham are expected to be featured in Phase 1, while Sigewinne and Furina in Phase 2. This will be Alhaitham’s second rerun banner after January 2023 and Furina’s first rerun.
Warning: These leaks are subject to change in the future. We always recommend waiting until the official 4.7 livestream confirms them.
Who Should You Pull for in Version 4.7?
As we discussed above, Version 4.7 might feature Clorinde, Alhaitham, Sigewinne, and Furina. Now, who should you pull for? The answer varies for each person. If you are lacking any good hydro SUPPORT or SUB-DPS, then Furina should be the way to go.
However, if you need a good DPS unit, then Alhaitham or Clorinde will be a better choice, depending on your team and playstyle. If you need an electro DPS, go for Clorinde, but if you prefer Dendro-oriented teams, Alhaitham will be the best choice for you.
Finally, if you need a healer, do not hesitate to pull for Sigewinne. She is a pretty good quick swap healer working exceptionally well with any character.
Version 4.7 will be packed with new content and plenty of resources. We will also be getting a new Archon quest and end-game content—a great source of primogems. However, it’s better to start saving now, as we are not sure about the exact primogems count.
So, which character will you be pulling for in Version 4.7? Let us know in the comment section.
Leave a Reply